5,246 Shares in Enovis Co. (NYSE:ENOV) Bought by Caxton Associates LP

Caxton Associates LP bought a new position in Enovis Co. (NYSE:ENOV) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,246 shares of the company’s stock, valued at approximately $237,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in Enovis by 19.9% during the 1st quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock worth $68,000 after purchasing an additional 180 shares during the period. Treasurer of the State of North Carolina grew its position in Enovis by 1.0% during the 4th quarter. Treasurer of the State of North Carolina now owns 23,252 shares of the company’s stock worth $1,303,000 after purchasing an additional 220 shares during the period. State of Michigan Retirement System grew its position in Enovis by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,202 shares of the company’s stock worth $762,000 after purchasing an additional 300 shares during the period. Swiss National Bank grew its position in Enovis by 0.3% during the 1st quarter. Swiss National Bank now owns 97,000 shares of the company’s stock worth $6,058,000 after purchasing an additional 300 shares during the period. Finally, Benjamin F. Edwards & Company Inc. grew its position in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ENOV shares. Needham & Company LLC dropped their target price on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. dropped their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Evercore ISI dropped their target price on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $69.13.

Enovis Trading Up 0.7 %

Shares of Enovis stock opened at $43.66 on Friday. The firm has a market capitalization of $2.44 billion, a PE ratio of -29.10 and a beta of 1.92. Enovis Co. has a twelve month low of $39.98 and a twelve month high of $65.03. The firm’s 50-day moving average price is $44.42 and its 200 day moving average price is $49.39. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. The firm had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. Enovis’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period last year, the company posted $0.61 EPS. On average, sell-side analysts predict that Enovis Co. will post 2.7 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.